Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
CASPOFUNGIN
McDermott Laboratories Ltd t/a Gerard Laboratories
J02AX04
CASPOFUNGIN
70 Milligram
Pdr/Conc/Soln for Infus
Product subject to prescription which may not be renewed (A)
caspofungin
Not Marketed
2017-07-28
Colours Non-Print Colours Date: Time: Dimensions Main Font Body Text Size Min Text Size used Page Count No. of colours Pharma Code SAP No. Vendor Job No. Trackwise Proof No. Client Market Keyline/Drawing No. Barcode Info Description Component Type Affiliate Item Code Superceded Affiliate Item Code TrackWise PR No. MA No. Packing Site/Printer Supplier Code Sign-offs PEPA+ Equivalent Pantone+ Color Bridge Coated colours v2/Oct 2016 1/2 1 Helvetica Neue LT Pro 310 x 600 mm 11 pt 11 pt Caspofungin Acetate 70 mg 1 Leaflet 1223925 NA 1223925 NA Galenicum Health, S.L. (Madrid - SP) PR1223925 NA NA 315476 2 Ireland NA NA Black 16:29 10 Jul 2017 1. What Caspofungin is and what it is used for 2. What you need to know before you are given Caspofungin 3. How to use Caspofungin 4. Possible side effects 5. How to store Caspofungin 6. Contents of the pack and other information Caspofungin Mylan 70 mg powder for concentrate for solution for infusion Caspofungin What is in this leaflet 1. What Caspofungin is and what it is used for What Caspofungin is Caspofungin belongs to a group of medicines called antifungals. What Caspofungin is used for Caspofungin is used to treat the following infections in children, adolescents and adults: • serious fungal infections in your tissues or organs (called ‘invasive candidiasis’). This infection is caused by fungal (yeast) cells called Candida. People who might get this type of infection include those who have just had an operation or those whose immune systems are weak. Fever and chills that do not respond to an antibiotic are the most common signs of this type of infection. • fungal infections in your nose, nasal sinuses or lungs (called ‘invasive aspergillosis’) if other anti‑fungal treatments have not worked or have caused side effects. This infection is caused by a mould called Aspergillus. People who might get this type of infection include those having chemotherapy, those who have had a transplant and those whose immune systems are weak. • suspected fungal infections if Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Caspofungin Mylan 70 mg powder for concentrate for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 70 mg caspofungin (as acetate). After reconstitution in 10.5 ml of water for injection, 1 ml of concentrate contains 7.2 mg caspofungin. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder for concentrate for solution for infusion. Before reconstitution, the product is a white to off-white compact powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS • Treatment of invasive candidiasis in adult or paediatric patients. • Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. • Empirical therapy for presumed fungal infections (such as_ Candida_ or_ Aspergillus_) in febrile, neutropaenic adult or paediatric patients. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Caspofungin should be initiated by a physician experienced in the management of invasive fungal infections. Posology _Adult patients_ A single 70 mg loading dose should be administered on Day-1, followed by 50 mg daily thereafter. In patients weighing more than 80 kg, after the initial 70 mg loading dose, caspofungin 70 mg daily is recommended (see section 5.2). No dosage adjustment is necessary based on gender or race (see section 5.2). _Paediatric patients (12 months to 17 years)_ In paediatric patients (12 months to 17 years of age), dosing should be based on the patient’s body surface area (see Instructions for Use in Paediatric Patients, Mosteller Formula). For all indications, a single 70-mg/m 2 loading dose (not to exceed an actual dose of 70 mg) should be administered on Day 1, followed by 50 mg/m 2 daily thereafter (not to exceed an Read the complete document